Semaglutide weight loss plateaus: what week 12 really means

What did @aubreysikeee actually say?

In week 12 of her semaglutide journey, the creator reported losing about half a pound that week and roughly 15 to 17 pounds total. She demonstrated a subcutaneous injection on camera, said she stays at "40 units" of compounded semaglutide, and mentioned experiencing vomiting and nausea on injection day and the day after. She closed with the reassurance: "don't get discouraged if you go a few weeks with no weight loss."

She also noted less protein intake and heavy travel as reasons for slower progress. The video is sponsored by MinuteMD, a telehealth platform offering compounded semaglutide. That relationship matters when evaluating how this content frames the drug's effects and the injection process.

Does the science back this up?

The broad arc of her experience, slower weeks, GI side effects, modest total loss at 12 weeks, is consistent with the clinical literature. But some specifics deserve scrutiny.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks. At week 12, most participants are still dose-escalating and losses are typically modest. Plateaus are not just normal, they are expected, especially early. Her reassurance to viewers on that point is genuinely accurate.

On GI side effects: nausea and vomiting are the most common adverse events with semaglutide. The same STEP 1 data showed nausea in roughly 44% of participants and vomiting in about 24%. Symptoms tend to cluster around dose escalation and injections, which tracks with her description of a 2-day window of sickness.

Protein intake is relevant. A 2021 review by Biolo et al. in Clinical Nutrition noted that adequate dietary protein helps preserve lean mass during caloric restriction. If she is eating less protein while losing weight, she risks losing muscle alongside fat, a legitimate concern her provider should address.

What did they get wrong (or right)?

A few things need flagging.

First, she describes her dose as ".4 or 40 units" without any clinical context about whether that is appropriate for her stage of treatment. Semaglutide dosing follows a structured escalation protocol for a reason: GI tolerance. Publicly demonstrating a specific numeric dose can mislead viewers into self-adjusting their own doses, which carries real risk. This writeup will not endorse any specific dose as a reference point.

Second, and more significant: she never distinguishes compounded semaglutide from brand-name Wegovy or Ozempic. Compounded semaglutide is not FDA-approved and is not equivalent to the branded drugs. The FDA has flagged compounded semaglutide products for quality and dosing inconsistencies. Viewers watching this as a straightforward product endorsement may not understand that difference.

What she got right: the injection technique shown, inserting subcutaneously, holding, then withdrawing, is broadly consistent with guidance for subcutaneous self-injection. Her framing of a weight plateau as normal rather than a failure is accurate and, frankly, more honest than a lot of content in this space. Credit where it is due.

What should you actually know?

If you are on compounded semaglutide or considering it, a few things matter more than this video suggests.

Compounded semaglutide is legal in limited circumstances but is not FDA-approved. The FDA issued warnings in 2023 and 2024 about compounded versions that may contain incorrect doses or impurities. You are not getting the same product as Wegovy when you use a compound pharmacy, and anyone who tells you otherwise is oversimplifying.

Persistent vomiting on injection day, as described here, is worth a conversation with your prescriber. It may indicate the current dose is too aggressive or that an anti-nausea strategy is needed. It is not something to just push through without clinical input.

Plateaus at week 12 are common. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that meaningful weight loss continues well beyond the 12-week mark for most patients, particularly as doses reach therapeutic levels. A slow week is not a sign the drug has stopped working.

Finally, protein intake on GLP-1 therapy matters more than most social content acknowledges. Work with a dietitian if you can, not just a telehealth app, to protect lean mass during active weight loss.